Efficacy and safety are the key considerations when it comes to choosing optimal therapies for inflammatory bowel disease (IBD). While recent studies have examined the comparative effectiveness of ...

Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...

Use of lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) to predict relapse in patients with diffuse large B-cell lymphoma (DLBCL). Background: Inflammatory bowel disease ...

Among biologic agents, vedolizumab (Entyvio) and ustekinumab (Stelara) are associated with lower rates of infection-related hospitalizations than anti-tumor necrosis factor (TNF) agents in older ...

Please provide your email address to receive an email when new articles are posted on . Mirikizumab, a monoclonal antibody poised to become first-in-class treatment for ulcerative colitis, has the ...

In a study, veterans who used TNF blockers to treat inflammatory bowel disease had an increased risk for kidney function decline. Anti-tumor necrosis factor (anti-TNF) therapy may increase the risk ...

Patients with both inflammatory bowel disease (IBD) and obesity starting on new biologic therapies do not face an increased risk for hospitalization, IBD-related surgery, or serious infection, reveals ...

Disruption of the gut microbiome is a feature of both conditions, but experts do not know if this gut dysbiosis underlies the link between the two diseases. A new study comparing the microbiomes of ...

DALLAS--(BUSINESS WIRE)--EnLiSense CCM, a pioneer in non-invasive, real-time inflammatory biomarker monitoring, announces the initiation of multiple groundbreaking clinical studies in collaboration ...

The AS and IBD Link Can AS Cause IBD? Treatments Lifestyle Remedies When to See a Doctor Ankylosing spondylitis (AS) is a chronic form of inflammatory arthritis that causes pain and stiffness in the ...